Yuekang Pharmaceutical (688658.SH) subsidiary YKYY033 injection obtains FDA clinical trial approval.

Zhitong Finance APP reported that YKANG Pharmaceutical (688658.SH) announced that its subsidiary, Beijing YKANG Kecyong Pharmaceutical Technology Co., Ltd., recently received a letter from the U.S. Food and Drug Administration (referred to as "FDA") approving the clinical trial application for YKYY033 injection for the prevention and treatment of venous and arterial thrombosis.